Phase 1Data readout

Bexobrutideg (NX-5948) (BTK Degrader)

Inflammation And Autoimmune Diseases

NRIXNurix Therapeutics

Expected catalystDecember 31, 2026Company guidance: Dec 31, 2026

Catalyst overview

Event details

Drug or asset: Bexobrutideg (NX-5948) (BTK Degrader)
Development stage: Phase 1
Event type: Data readout
Indication: Inflammation And Autoimmune Diseases

Research summary

What is being tracked?

This catalyst tracks a Phase 1 data readout for Bexobrutideg (NX-5948) (BTK Degrader) in Inflammation And Autoimmune Diseases. The expected timing is based on the latest available company guidance and may change.

Development notes

07/09/26:- CSU data presented; Phase 2 CSU and MS planning underway. 08/04/26:- Tablet formulation evaluated in healthy volunteer SAD/MAD study NCT06717269.

Verification

Primary source

Confirm timing and program details against the company announcement or filing.

Open source

Bexobrutideg (NX-5948) (BTK Degrader)

Event details

What is being tracked?

Development notes

Primary source

Related pipeline programs

Bexobrutideg (NX-5948)

Bexobrutideg (NX-5948)

GS-6791 (NX-0479)

Zelebrudomide (NX-2127)